Drug - Opsumit® (macitentan) [Actelion Pharmaceuticals US, Inc.]
March 2014
Therapeutic area - Pulmonary arterial hypertension (PAH)
Patient has a diagnosis of PAH.
Quantity limit = 34
OPSUMIT® is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension to delay disease progression. Due to the potential for fetal harm, OPSUMIT® requires a restricted distribution program for females.
MHCP Provider Call Center 651-431-2700 or 800-366-5411
